Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00260065 · ClinicalTrials.gov registry record · Phase 2
A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
NCT00260065 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 99 participants.
The verdict
NCT00260065, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the overall response rate in patients with myelodysplastic syndromes (MDS) given a daily dosing schedule of decitabine.
Interventions
- DRUG Decitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2005-05 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00260065
The ClinicalTrials.gov registry entry for NCT00260065 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Decitabine is the first listed.
NCT00260065 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00260065 about?
NCT00260065 is a clinical study titled "A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes". The purpose of this study is to determine the overall response rate in patients with myelodysplastic syndromes (MDS) given a daily dosing schedule of decitabine.
What is the current status of trial NCT00260065?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2005-05. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00260065?
The interventions under investigation include: Decitabine (DRUG).
Who is sponsoring clinical trial NCT00260065?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.